MedTrace Logo

Modulation of Gut Microbiota in Early Sepsis: A Pilot Study

NCT02469571 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-03-29

No results posted yet for this study

Summary

Background Sepsis is a common disease leading to high morbidity and mortality. Gut microbiota and/or gut permeability may play a crucial role in the development of organ dysfunction.

Hypothesis The ingestion of a multispecies probiotic in early sepsis is able to modulate gut microbiota and/or gut permeability.

Conditions

Interventions

DIETARY_SUPPLEMENT

Winclove 607

multispecies probiotic

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Vanessa Stadlbauer-Köllner, MD · Medical University of Graz

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2016-07-31
Completion
2018-03-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02469571 on ClinicalTrials.gov